Sarah Fidler

Q: What Schools Are Affiliated With Sarah Fidler

Sarah Fidler is affiliated with the following schools: Imperial College London, Stanford University, University of California, San Francisco

Sarah Fidler's AcademicInfluence.com Rankings

Sarah Fidler

Biology

#14827

World Rank

#18682

Historical Rank

Immunology

#1021

World Rank

#1047

Historical Rank

biology Degrees

Download Badge

Biology

Sarah Fidler's Degrees

PhD Immunology Stanford University
Doctorate Medicine University of California, San Francisco

Why Is Sarah Fidler Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Sarah Fidler is an immunologist, researcher and professor in HIV Medicine at Imperial College London and consultant physician in HIV for St Mary's Hospital, London. Her clinical work involves looking after people who have just been infected with the human immunodeficiency virus , and testing new approaches towards curing HIV.

(See a Problem?)

Sarah Fidler's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation (2010) (1129)
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study (2019) (512)
Adaptation of HIV-1 to human leukocyte antigen class I (2009) (475)
British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012 (2012) (387)
International AIDS Society global scientific strategy: towards an HIV cure 2016 (2016) (372)
Adherence to antiretroviral therapy in adolescents living with HIV: systematic review and meta-analysis (2014) (323)
HIV-1 DNA predicts disease progression and post-treatment virological control (2014) (267)
Short-course antiretroviral therapy in primary HIV infection. (2013) (208)
HPTN 071 (PopART): Rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment – a study protocol for a cluster randomised trial (2014) (198)
British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.) (2014) (195)
Uptake of Home-Based Voluntary HIV Testing in Sub-Saharan Africa: A Systematic Review and Meta-Analysis (2012) (195)
Effect of Universal Testing and Treatment on HIV Incidence - HPTN 071 (PopART). (2019) (185)
Reductions in HIV transmission risk behaviour following diagnosis of primary HIV infection: a cohort of high‐risk men who have sex with men (2009) (168)
British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2015 (2016) (140)
Immunological biomarkers predict HIV-1 viral rebound after treatment interruption (2015) (139)
Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection (2016) (122)
HPTN 071 (PopART): A Cluster-Randomized Trial of the Population Impact of an HIV Combination Prevention Intervention Including Universal Testing and Treatment: Mathematical Model (2014) (111)
Ultrasensitive Detection and Phenotyping of CD4+ T Cells with Optimized HLA Class II Tetramer Staining1 (2005) (106)
Sexual transmission of HIV-1. (2010) (105)
A universal testing and treatment intervention to improve HIV control: One-year results from intervention communities in Zambia in the HPTN 071 (PopART) cluster-randomised trial (2017) (104)
Clinical and public health implications of acute and early HIV detection and treatment: a scoping review (2017) (96)
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial (2021) (93)
B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection (2010) (84)
How important is the 'quality' of the cytotoxic T lymphocyte (CTL) response in protection against HIV infection? (2001) (81)
Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection. (2012) (81)
A systematic review of definitions of extreme phenotypes of HIV control and progression (2013) (79)
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021 (2021) (78)
Tracking Virus-Specific CD4+ T Cells during and after Acute Hepatitis C Virus Infection (2007) (78)
Epigenetic scars of CD8+ T cell exhaustion persist after cure of chronic infection in humans (2021) (75)
Duration of HIV-1 Viral Suppression on Cessation of Antiretroviral Therapy in Primary Infection Correlates with Time on Therapy (2013) (75)
Impaired IFN-γ-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART (2006) (72)
What do the Universal Test and Treat trials tell us about the path to HIV epidemic control? (2020) (71)
Community based distribution of oral HIV self-testing kits in Zambia: a cluster-randomised trial nested in four HPTN 071 (PopART) intervention communities (2018) (70)
Plasma HIV Viral Rebound following Protocol-Indicated Cessation of ART Commenced in Primary and Chronic HIV Infection (2012) (70)
Universal Testing and Treatment as an HIV Prevention Strategy: Research Questions and Methods (2011) (70)
Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection (2002) (69)
Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom (2007) (68)
Low levels of HIV test coverage in clinical settings in the UK: a systematic review of adherence to 2008 guidelines (2014) (66)
Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial (2020) (64)
Clinical implications of stopping nevirapine‐based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance (2004) (63)
HIV-1-specific CD4+ T lymphocyte turnover and activation increase upon viral rebound. (2005) (60)
Impact of a universal testing and treatment intervention on HIV incidence in Zambia and South Africa: results of the HPTN 071 (PopART) community-randomized trial (2019) (56)
Crossing the divide: transition care services for young people with HIV-their views. (2011) (56)
The Detection and Management of Early HIV Infection: A Clinical and Public Health Emergency (2013) (55)
HLA-Associated Clinical Progression Correlates with Epitope Reversion Rates in Early Human Immunodeficiency Virus Infection (2008) (52)
Survival following HIV infection of a cohort followed up from seroconversion in the UK (2008) (47)
Post-treatment control or treated controllers? Viral remission in treated and untreated primary HIV infection (2017) (46)
HIV-related stigma and universal testing and treatment for HIV prevention and care: design of an implementation science evaluation nested in the HPTN 071 (PopART) cluster-randomized trial in Zambia and South Africa. (2016) (46)
Postexposure prophylaxis, preexposure prophylaxis or universal test and treat: the strategic use of antiretroviral drugs to prevent HIV acquisition and transmission (2010) (46)
Can Combination Prevention Strategies Reduce HIV Transmission in Generalized Epidemic Settings in Africa? The HPTN 071 (PopART) Study Plan in South Africa and Zambia (2013) (46)
Enhanced normalisation of CD4/CD8 ratio with early antiretroviral therapy in primary HIV infection (2014) (46)
Controlling the HIV Epidemic with Antiretrovirals (2013) (45)
High rates of asymptomatic neurocognitive impairment in vertically acquired HIV-1-infected adolescents surviving to adulthood. (2010) (45)
Understanding the Time Needed to Link to Care and Start ART in Seven HPTN 071 (PopART) Study Communities in Zambia and South Africa (2018) (43)
Increasing incidence of acute hepatitis C in individuals diagnosed with primary HIV in the United Kingdom. (2008) (43)
Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial (2021) (43)
Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK (2010) (41)
Quantifying HIV transmission flow between high-prevalence hotspots and surrounding communities: a population-based study in Rakai, Uganda (2020) (41)
Challenges of HIV diagnosis and management in the context of pre‐exposure prophylaxis (PrEP), post‐exposure prophylaxis (PEP), test and start and acute HIV infection: a scoping review (2019) (41)
Failure to detect xenotropic murine leukemia virus-related virus in blood of individuals at high risk of blood-borne viral infections. (2010) (41)
Towards 90-90: Findings after two years of the HPTN 071 (PopART) cluster-randomized trial of a universal testing-and-treatment intervention in Zambia (2018) (41)
Transmitted drug‐resistant HIV‐1 in primary HIV‐1 infection; incidence, evolution and impact on response to antiretroviral therapy (2006) (40)
Histone Deacetylase Inhibitors Enhance CD4 T Cell Susceptibility to NK Cell Killing but Reduce NK Cell Function (2016) (40)
Variable fate of virus‐specific CD4+ T cells during primary HIV‐1 infection (2001) (40)
Community intervention improves knowledge of HIV status of adolescents in Zambia: findings from HPTN 071-PopART for youth study (2017) (40)
Antiretroviral treatment of primary HIV infection to reduce onward transmission (2010) (39)
Differences in HIV-Specific T Cell Responses between HIV-Exposed and -Unexposed HIV-Seronegative Individuals (2011) (38)
"Payment by Results"--financial incentives and motivational interviewing, adherence interventions in young adults with perinatally acquired HIV-1 infection: a pilot program. (2014) (37)
Predictors of timely linkage‐to‐ART within universal test and treat in the HPTN 071 (PopART) trial in Zambia and South Africa: findings from a nested case‐control study (2017) (37)
Quantifying sexual exposure to HIV within an HIV-serodiscordant relationship: development of an algorithm (2011) (37)
Direct ex vivo analysis reveals distinct phenotypic patterns of HIV‐specific CD8+ T lymphocyte activation in response to therapeutic manipulation of virus load (2001) (36)
The British HIV Association/British Association for Sexual Health and HIV Position Statement on pre-exposure prophylaxis in the UK (2012) (36)
A global survey of HIV‐positive people's attitudes towards cure research (2017) (35)
Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort (2007) (35)
Optimizing antiretroviral therapy in adolescents with perinatally acquired HIV-1 infection (2010) (34)
CD32-Expressing CD4 T Cells Are Phenotypically Diverse and Can Contain Proviral HIV DNA (2018) (34)
Primary HIV infection: to treat or not to treat? (2008) (34)
What works – reaching universal HIV testing: lessons from HPTN 071 (PopART) trial in Zambia (2017) (33)
Structured Observations Reveal Slow HIV-1 CTL Escape (2015) (33)
Tracking the progress of HIV: the impact of point-of-care tests on antiretroviral therapy (2013) (32)
Brief Report: Enhanced Normalization of CD4/CD8 Ratio With Earlier Antiretroviral Therapy at Primary HIV Infection (2016) (32)
Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression (2014) (32)
Importance of Self-Motivation and Social Support in Medication Adherence in HIV-Infected Adolescents in the United Kingdom and Ireland: A Multicentre HYPNet Study. (2015) (32)
Sexual Transmission of Single Human Immunodeficiency Virus Type 1 Virions Encoding Highly Polymorphic Multisite Cytotoxic T-Lymphocyte Escape Variants (2005) (31)
Passive Sexual Transmission of Human Immunodeficiency Virus Type 1 Variants and Adaptation in New Hosts (2006) (30)
Early antiretroviral therapy reduces HIV DNA following perinatal HIV infection (2017) (28)
Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers (2017) (28)
The Role of CD4+ T Follicular Helper Cells in HIV Infection: From the Germinal Center to the Periphery (2017) (28)
Baseline CD4 Count and Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis (2016) (27)
HIV-1-specific CD4+ responses in primary HIV-1 infection predict disease progression (2014) (27)
Intimate relationships in young adults with perinatally acquired HIV: Partner considerations (2013) (27)
A Comprehensive Genomics Solution for HIV Surveillance and Clinical Monitoring in Low-Income Settings (2020) (27)
Dynamics of immunoglobulin sequence diversity in HIV-1 infected individuals (2015) (27)
Using nearly full-genome HIV sequence data improves phylogeny reconstruction in a simulated epidemic (2016) (26)
A review of transition experiences in perinatally and behaviourally acquired HIV-1 infection; same, same but different? (2017) (26)
Virological Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary HIV Infection (2016) (25)
Comparative potency of three antiretroviral therapy regimes in primary HIV infection (2006) (25)
“The difference that makes a difference”: highlighting the role of variable contexts within an HIV Prevention Community Randomised Trial (HPTN 071/PopART) in 21 study communities in Zambia and South Africa (2016) (24)
Understanding low sensitivity of community-based HIV rapid testing: experiences from the HPTN 071 (PopART) trial in Zambia and South Africa (2017) (24)
The cascade of care following community-based detection of HIV in sub-Saharan Africa – A systematic review with 90-90-90 targets in sight (2018) (24)
Correlation between CSF and blood neurofilament light chain protein: a systematic review and meta-analysis (2021) (23)
Clinical evaluation of the Determine HIV-1/2 Ag/Ab Combo test. (2012) (23)
Differences in health-related quality of life between HIV-positive and HIV-negative people in Zambia and South Africa: a cross-sectional baseline survey of the HPTN 071 (PopART) trial (2017) (23)
A highly virulent variant of HIV-1 circulating in the Netherlands (2022) (23)
Phylogenetic analysis consistent with a clinical history of sexual transmission of HIV-1 from a single donor reveals transmission of highly distinct variants (2011) (22)
Advancing the HIV cure agenda: the next 5 years (2015) (21)
Variable fate of virus-specific CD4(+) T cells during primary HIV-1 infection. (2001) (21)
Stigma and Judgment Toward People Living with HIV and Key Population Groups Among Three Cadres of Health Workers in South Africa and Zambia: Analysis of Data from the HPTN 071 (PopART) Trial. (2020) (20)
Position statement on the use of antiretroviral therapy to reduce HIV transmission, January 2013: The British HIV Association (BHIVA) and the Expert Advisory Group on AIDS (EAGA) (2013) (20)
Increased levels of CD4 T-cell activation in individuals with CXCR4 using viruses in primary HIV-1 infection (2012) (20)
Oral pemphigus vulgaris associated with HIV infection. (2003) (20)
Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports (2016) (20)
Prevalence of primary genotypic resistance in a UK centre: comparison of primary HIV-1 and newly diagnosed treatment-naive individuals (2007) (20)
CD32 expressing doublets in HIV-infected gut-associated lymphoid tissue are associated with a T follicular helper cell phenotype (2019) (20)
Restriction of V3 region sequence divergence in the HIV-1 envelope gene during antiretroviral treatment in a cohort of recent seroconverters (2013) (19)
Maintenance of Functional CD57+ Cytolytic CD4+ T Cells in HIV+ Elite Controllers (2019) (19)
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV (2022) (19)
Intimate relationships in young adults with perinatally acquired HIV: a qualitative study of strategies used to manage HIV disclosure. (2016) (19)
HIV-1 drug resistance in primary infections in the UK (2001) (18)
Antiretroviral adherence for adolescents growing up with HIV: understanding real life, drug delivery and forgiveness (2020) (17)
Incidence of Tuberculosis Among HIV-Positive Individuals Initiating Antiretroviral Treatment at Higher CD4 Counts in the HPTN 071 (PopART) Trial in South Africa (2017) (17)
Sexually Transmitted Bedfellows: Exquisite Association Between HIV and Herpes Simplex Virus Type 2 in 21 Communities in Southern Africa in the HIV Prevention Trials Network 071 (PopART) Study (2018) (17)
Cost and cost-effectiveness of a universal HIV testing and treatment intervention in Zambia and South Africa: evidence and projections from the HPTN 071 (PopART) trial (2021) (17)
How Many HIV Infections May Be Averted by Targeting Primary Infection in Men Who Have Sex With Men? Quantification of Changes in Transmission-Risk Behavior, Using an Individual-Based Model (2014) (16)
Soluble plasma programmed death 1 (PD-1) and Tim-3 in primary HIV infection (2019) (15)
Clinical outcomes post transition to adult services in young adults with perinatally acquired HIV infection: mortality, retention in care, and viral suppression. (2020) (15)
Attrition when providing antiretroviral treatment at CD4 counts >500cells/μL at three government clinics included in the HPTN 071 (PopART) trial in South Africa (2018) (15)
Hospital‐based routine HIV testing in high‐income countries: a systematic literature review (2018) (15)
A pilot evaluation of whole blood finger-prick sampling for point-of-care HIV viral load measurement: the UNICORN study (2017) (14)
The effect of short-course antiretroviral therapy initiated in primary HIV-1 infection on interleukin-6 and D-dimer levels (2015) (14)
A heterogeneous human immunodeficiency virus-like particle (VLP) formulation produced by a novel vector system (2018) (14)
Spinning plates: livelihood mobility, household responsibility and anti‐retroviral treatment in an urban Zambian community during the HPTN 071 (PopART) study (2018) (14)
Sexual and reproductive health in a UK cohort of young adults perinatally infected with HIV (2013) (14)
Parenting considerations in young adults with perinatally acquired HIV (2014) (14)
A randomised controlled trial comparing the impact of antiretroviral therapy (ART) with a "Kick-and-Kill" approach to ART alone on HIV reservoirs in individuals with primary HIV infection (PHI); RIVER trial (2018) (14)
Social response to the delivery of HIV self-testing in households: experiences from four Zambian HPTN 071 (PopART) urban communities (2020) (14)
A qualitative study exploring the social and environmental context of recently acquired HIV infection among men who have sex with men in South-East England (2017) (13)
Optimizing HIV transition services for young adults (2018) (13)
HIV testing and treatment coverage achieved after 4 years across 14 urban and peri-urban communities in Zambia and South Africa: An analysis of findings from the HPTN 071 (PopART) trial (2020) (13)
A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens (2017) (13)
Levels of Human Immunodeficiency Virus DNA Are Determined Before ART Initiation and Linked to CD8 T-Cell Activation and Memory Expansion (2019) (13)
CD4+ T‐cell recognition of diverse clade B HIV‐1 isolates (1997) (13)
HIV testing uptake and acceptability in an inner city polyclinic (2012) (12)
Who Accepts and Who Uses Community-Based Secondary Distribution HIV Self-Testing (HIVST) Kits? Findings From the Intervention Arm of a Cluster-Randomized Trial of HIVST Distribution Nested in Four HPTN 071 (PopART) Communities in Zambia (2020) (12)
BHIVA – BASHH Position Statement on PrEP in UK Second Update May 2016 (2016) (12)
HIV Stigma and Viral Suppression Among People Living With HIV in the Context of Universal Test and Treat: Analysis of Data From the HPTN 071 (PopART) Trial in Zambia and South Africa (2020) (12)
Mean Corpuscular Volume as a Marker for Adherence to Zidovudine-Containing Therapy in HIV-Infected Adults (2012) (12)
Reasons for delayed antiretroviral therapy (ART) initiation in the era of early ART initiation guidelines: a retrospective service evaluation (2019) (12)
Engaging young people in the design of a sexual reproductive health intervention: Lessons learnt from the Yathu Yathu (“For us, by us”) formative study in Zambia (2021) (11)
Transition to adult services – a positive step (2017) (11)
Resistance to HIV drugs in UK may be lower in some areas (2006) (11)
Laboratory adverse events and discontinuation of therapy according to CD4+ cell count at the start of antiretroviral therapy (2014) (11)
Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies. (2012) (11)
HIV Care Cascade Among Adolescents in a “Test and Treat” Community-Based Intervention: HPTN 071 (PopART) for Youth Study (2020) (10)
Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection (2021) (10)
Cerebral function in perinatally HIV-infected young adults and their HIV-uninfected sibling controls (2015) (10)
Primary HIV (2006) (10)
Association between HIV stigma and antiretroviral therapy adherence among adults living with HIV: baseline findings from the HPTN 071 (PopART) trial in Zambia and South Africa (2020) (10)
Position statement on the use of antiretroviral therapy to reduce HIV transmission . September 2014 (2014) (9)
HIV prevention 2010: where are we now and where are we going? (2010) (9)
Human MAIT cells respond to and suppress HIV-1 (2021) (9)
Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial (2022) (9)
Special Issue: British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (2013 update) (2014) (9)
Better Virological Outcomes Among People Living With Human Immunodeficiency Virus (HIV) Initiating Early Antiretroviral Treatment (CD4 Counts ≥500 Cells/µL) in the HIV Prevention Trials Network 071 (PopART) Trial in South Africa (2019) (9)
HIV Treatment-As-Prevention Research: Taking the Right Road at the Crossroads (2015) (9)
Clinical outcomes of patients with and without HIV hospitalized with COVID‐19 in England during the early stages of the pandemic: a matched retrospective multi‐centre analysis (RECEDE‐C19 study) (2021) (9)
A comprehensive genomics solution for HIV surveillance and clinical monitoring in a global health setting (2018) (9)
The effect of universal testing and treatment on HIV stigma in 21 communities in Zambia and South Africa (2020) (9)
Role of HIV Infection Duration and CD4 Cell Level at Initiation of Combination Anti-Retroviral Therapy on Risk of Failure (2013) (8)
Human immunodeficiency virus (HIV)‐specific T helper responses fail to predict CD4+ T cell decline following short‐course treatment at primary HIV‐1 infection (2008) (8)
A study on the dynamics of temporary HIV treatment to assess the controversial outcomes of clinical trials: An in-silico approach (2018) (8)
Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation (2015) (8)
Responses to Quadrivalent Influenza Vaccine Reveal Distinct Circulating CD4+CXCR5+ T Cell Subsets in Men Living with HIV (2019) (8)
Virological remission after antiretroviral therapy interruption in female African HIV seroconverters (2019) (7)
Antigen presenting cell function in HIV-1 infected patients. (1999) (7)
Risk of HIV transmission in discordant partners. (2007) (7)
Comparison of Sexual Behavior and HIV Risk between Two HIV-1 Serodiscordant Couple Cohorts: The CHAVI 002 Study (2012) (7)
Quantifying the contribution of different aged men and women to onwards transmission of HIV-1 in generalised epidemics in sub-Saharan Africa: A modelling and phylogenetics approach from the HPTN071 (PopART) trial (2019) (7)
Determination of HIV status and identification of incident HIV infections in a large, community‐randomized trial: HPTN 071 (PopART) (2020) (6)
A targeted reactivation of latent HIV-1 using an activator vector in patient samples from acute infection (2020) (6)
Mapping the drivers of within-host pathogen evolution using massive data sets (2017) (6)
Altruism and medical advice are key factors in decision-making about participating in HIV cure research: Results from a UK-wide survey of people living with HIV (2015) (6)
Malignancy and all-cause mortality; incidence in adolescents and young adults living with perinatally acquired HIV (2020) (6)
Universal HIV testing and treatment and HIV stigma reduction: a comparative thematic analysis of qualitative data from the HPTN 071 (PopART) trial in South Africa and Zambia (2020) (6)
Highlights from the 22nd International AIDS Conference (AIDS 2018), 22–27 July 2018, Amsterdam, the Netherlands (2018) (6)
CD4 (2018) (6)
Insaka: mobile phone support groups for adolescent pregnant women living with HIV (2021) (6)
Longitudinal analysis of an HLA-B*51-restricted epitope in integrase reveals immune escape in early HIV-1 infection (2013) (6)
HIV cure research in the time of COVID-19 - Antiretroviral therapy treatment interruption trials: A discussion paper (2020) (6)
Work and home productivity of people living with HIV in Zambia and South Africa (2019) (6)
Careful consideration when responding to new data: dolutegravir and pregnancy (2018) (6)
Epigenetic Features of HIV-Induced T-Cell Exhaustion Persist Despite Early Antiretroviral Therapy (2021) (6)
Enhanced normalisation of CD 4 / CD 8 ratio with early antiretroviral therapy in primary HIV infection (2015) (6)
Assessment of Anti–HIV-1 Antibodies in Oral and Nasal Compartments of Volunteers From 3 Different Populations (2016) (6)
A systematic review of the effectiveness of non- health facility based care delivery of antiretroviral therapy for people living with HIV in sub-Saharan Africa measured by viral suppression, mortality and retention on ART (2021) (6)
Retrospective review of routine clinical patient experiences with dolutegravir; virological suppression, immunological recovery and adverse events (2017) (5)
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus (2022) (5)
Impact of a community-wide combination HIV prevention intervention on knowledge of HIV status among adolescents (2020) (5)
Expression of type I interferon-associated genes at antiretroviral therapy interruption predicts HIV virological rebound (2022) (5)
PopART-IBM, a highly efficient stochastic individual-based simulation model of generalised HIV epidemics developed in the context of the HPTN 071 (PopART) trial (2020) (5)
The under-representation of BAME patients in the COVID-19 Recovery trial at a major London NHS Trust (2020) (5)
Updated BHIVA-BASHH Position Statement on PrEP in the UK (2015) (5)
Compromised CD4:CD8 ratio recovery in people living with HIV aged over 50 years: an observational study (2019) (5)
Correlation between cerebrospinal fluid and plasma neurofilament light protein in treated HIV infection: results from the COBRA study (2021) (5)
How ‘place’ matters for addressing the HIV epidemic: evidence from the HPTN 071 (PopART) cluster-randomised controlled trial in Zambia and South Africa (2021) (5)
HIV cure strategies: response to ignore the central nervous system at your patients' peril. (2017) (4)
Optimising Xpert-Ultra and culture testing to reliably measure tuberculosis prevalence in the community: findings from surveys in Zambia and South Africa (2022) (4)
Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses (2021) (4)
Community-based distribution of oral HIV self-testing kits: experimental evidence from Zambia (2018) (4)
LB IMPACT OF UNIVERSAL TESTING AND TREATMENT IN ZAMBIA AND SOUTH AFRICA : HPTN 071 ( POPART ) (2019) (4)
Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa (2016) (4)
Prophylactic antiretroviral HIV therapy prevents infection in heterosexual men and women (2013) (4)
Novel therapies/hopes for HIV cure in perinatally acquired HIV-positive adolescents (2018) (4)
HIV genotyping and phylogenetics in the HPTN 071 (PopART) study: validation of a high-throughput sequencing assay for viral load quantification, genotyping, resistance testing and high-resolution transmission networking (2019) (4)
Hepatocellular Carcinoma in Perinatally Acquired HIV and HBV Coinfection: A Case Report. (2017) (4)
A comparison of different community models of antiretroviral therapy delivery with the standard of care among stable HIV+ patients: rationale and design of a non-inferiority cluster randomized trial, nested in the HPTN 071 (PopART) study (2021) (4)
Validation of population‐level HIV‐1 incidence estimation by cross‐sectional incidence assays in the HPTN 071 (PopART) trial (2021) (4)
Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity (2022) (3)
Community-based health workers implementing universal access to HIV testing and treatment: lessons from South Africa and Zambia—HPTN 071 (PopART) (2021) (3)
The importance of viral blips and duration of therapy initiated in primary infection in maintaining viral control after stopping cART (2014) (3)
Uptake of HIV Testing Services Through Novel Community-Based Sexual and Reproductive Health Services: An Analysis of the Pilot Implementation Phase of the Yathu Yathu Intervention for Adolescents and Young People Aged 15–24 in Lusaka, Zambia (2021) (3)
Short Communication: Lack of Effect of Maraviroc Intensification on Blood and Gut Reservoir. (2016) (3)
BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022 (2022) (3)
The impact of immunoglobulin in acute HIV infection on the HIV reservoir: a randomized controlled trial (2017) (3)
The Impact of HCV Infection Duration on HIV Disease Progression and Response to cART amongst HIV Seroconverters in the UK (2015) (3)
Immunotherapeutic approaches to HIV cure and remission. (2021) (3)
Enrichment of the HIV reservoir in CD32+ CD4 T cells occurs early in blood and tissue (2017) (2)
Acceptability and Preferences of Two Different Community Models of ART Delivery in a High Prevalence Urban Setting in Zambia: Cluster-Randomized Trial, Nested in the HPTN 071 (PopART) Study (2021) (2)
CD4:CD8 ratio in children with perinatally acquired HIV‐1 infection† (2018) (2)
Viral suppression and self-reported ART adherence after 3 years of universal testing and treatment in the HPTN 071 (PopART) community-randomised trial in Zambia and South Africa: a cross-sectional analysis (2022) (2)
The effect of Maraviroc intensification on gut reservoir and immune function in HIV-1-infected individuals receiving antiretroviral therapy with suboptimal CD4+T cell recovery (2016) (2)
Primary HIV infection: a medical and public health emergency requiring rapid specialist management. (2016) (2)
Launching a multidisciplinary European collaboration towards a cure for HIV: The EU2Cure Consortium (2021) (2)
Adapting community-based sexual and reproductive health services for adolescents and young people aged 15-24 years in response to COVID-19 in Lusaka, Zambia: the implications on the uptake of HIV testing services (2022) (2)
Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies (2022) (2)
The act of telling: South African women’s narratives of HIV status disclosure to intimate partners in the HPTN 071 (PopART) HIV prevention trial (2021) (2)
Enrichment of the HIV reservoir in CD32+CD4 T cells occurs early and is closely associated with immune checkpoint receptor expression (2017) (2)
Psychotic disorders in young adults with perinatally acquired HIV: a UK case series (2020) (2)
P07-09. Contemporaneous transmission of genetically distinct HIV variants from a single donor to two recipients (2009) (2)
An exploration of how broadly neutralizing antibodies might induce HIV remission: the ‘vaccinal’ effect (2022) (2)
IAS Towards an HIV Cure Symposium: people focused, science driven (2015) (2)
Yathu Yathu ("For us, by us"): Design of a cluster-randomised trial of the impact of community-based, peer-led comprehensive sexual and reproductive health services for adolescents and young people aged 15 to 24 in Lusaka, Zambia. (2021) (2)
Highlights of the 10th International AIDS Society (IAS) Conference on HIV Science, 21–25 July 2019, Mexico City, Mexico (2019) (2)
Evaluation of multi-assay algorithms for identifying individuals with recent HIV infection: HPTN 071 (PopART) (2021) (2)
Rates of viral suppression in a cohort of people with stable HIV from two community models of ART delivery versus facility-based HIV care in Lusaka, Zambia: a cluster-randomised, non-inferiority trial nested in the HPTN 071 (PopART) trial (2021) (2)
Demographic characteristics of sources of HIV-1 transmission in Zambia (2021) (2)
Rates of viral suppression in a cohort of people with stable HIV from two community models of ART delivery versus facility-based HIV care in Lusaka, Zambia: a cluster-randomised, non-inferiority trial nested in the HPTN 071 (PopART) trial (2021) (2)
Enhanced immune responses following heterologous vaccination with self-amplifying RNA and mRNA COVID-19 vaccines (2022) (2)
UK clinicians' approach to ART in primary HIV infection; comparison with the BHIVA guidelines (2015) (1)
Cross-sectional study of CD4:CD8 ratio recovery in young adults with perinatally acquired HIV-1 infection (2018) (1)
Balancing the need to rapidly scale-up and improve clinical outcomes in antiretroviral programmes in developing countries: lessons from an Indian programmatic cohort study. (2014) (1)
HIV-infected individuals co-infected with hepatitis C appear to have faster CD4 decline in the absence of ART but similar response once combination ART is initiated. (2009) (1)
The effect of HCV infection duration on HIV disease progression (2014) (1)
Case series of infertility amongst young women with perinatally acquired HIV: data from a London cohort (2019) (1)
OP 1.9 – 00042 Measuring the impact of early 3BNC117 intervention at ART initiation on the productive reservoir in a cohort of diverse viral subtypes: results from the VIP-SPOT assay in the eCLEAR trial (2022) (1)
Strategies to guide HIV prevention approaches: Correlation of sexually transmitted infections and sexual behaviour with risk of HIV infection (2013) (1)
PLOS Medicine 2017 Reviewer and Editorial Board Thank You (2018) (1)
Use of point-of-care C-reactive protein testing for screening of tuberculosis in the community in high-burden settings: a prospective, cross-sectional study in Zambia and South Africa. (2023) (1)
Outcomes of fertility investigations in a cohort of adults with perinatally acquired HIV-1 infection: a UK cross-sectional observational study (2020) (1)
HPTN 069/ACTG A5305: phase II study of maraviroc-containing regimens for HIV PrEP in US women; Postive impact of a randomized controlled trial of the Uthando Lwethu ("Our Love") intervention on rates of couples HIV testing in rural South Africa (2016) (1)
A public health approach to addressing and preventing misdiagnosis in the scale‐up of HIV rapid testing programmes (2017) (1)
Impact of universal testing and treatment on sexual risk behaviour and herpes simplex virus type 2: a prespecified secondary outcomes analysis of the HPTN 071 (PopART) community-randomised trial (2022) (1)
HIV Care and Service Development O 1 Non-AIDS mortality among people diagnosed with HIV in the era of highly-active antiretroviral therapy compared to the general population : England and Wales , 1997 – 2012 (2016) (1)
The association between HIV stigma and HIV incidence in the context of universal testing and treatment: analysis of data from the HPTN 071 (PopART) trial in Zambia and South Africa (2022) (1)
Engineered affinity-enhanced immune-mobilising monoclonal T cell receptors (ImmTAVs) for HIV cure (2017) (1)
Characterisation, Evaluation and Clinical Significance of Latent HIV-1 Reservoirs and Therapeutic Strategies for HIV Eradication (2011) (1)
Tale of two viruses: parvovirus B19 and HIV (2021) (1)
Author response: HIV-1 DNA predicts disease progression and post-treatment virological control (2014) (1)
Track E Implementation Science, Health Systems and Economics (2012) (1)
Post-treatment control: A functional cure for HIV (2015) (1)
HIV drug resistance in a community‐randomized trial of universal testing and treatment: HPTN 071 (PopART) (2022) (1)
Vedolizumab use and the associations between α4β7 expression and HIV reservoir in the gut during treated primary HIV infection. (2019) (1)
Response to ‘The use of tenofovir in patients with COVID‐19’ (2022) (1)
Disseminating complex primary outcome results from a community-randomised trial to Zambian communities: lessons learned using a community dialogue approach in the HPTN 071 (PopART) trial. (2022) (1)
The impact of vorinostat and therapeutic vaccine on gut HIV DNA: the RIVER gut study (2019) (1)
Response to Hepatitis B virus vaccine in young adults with perinatally acquired HIV infection. (2015) (1)
Impact of antiretroviral therapy in primary HIV infection on natural killer cell function and the association with viral rebound and HIV DNA following treatment interruption (2022) (1)
Missed opportunities for identifying primary HIV within genitourinary medical/HIV services (2012) (1)
HIV-1 Vpr drives a tissue residency-like phenotype during selective infection of resting memory T cells (2021) (1)
Could we, should we? Yes. (2011) (1)
A Randomized Comparison of Antiretroviral Therapy Alone Versus Antiretroviral Therapy with a 'Kick-and-Kill' Approach, on Measures of the HIV Reservoir Amongst Participants with Recent HIV Infection: The RIVER Trial (2019) (1)
Analysis Plan for Individual-based Model Projections of the HPTN 071 ( PopART ) Intervention (2018) (1)
Projected outcomes of universal testing and treatment in a generalised HIV epidemic in Zambia and South Africa (the HPTN 071 [PopART] trial): a modelling study (2022) (1)
Persistent elevation of Tim-3 and PD-1 on memory T cells despite early ART initiation during primary HIV infection (2019) (1)
Correlation between cerebrospinal fluid and blood neurofilament light protein: A systematic review and meta‐analysis (2020) (1)
Mitigation strategies to safely conduct HIV treatment research in the context of COVID‐19 (2022) (1)
Protective HLA class I alleles are associated with reduced immune activation and fibrinolysis in individuals with primary HIV infection (2010) (1)
Tolerability of four‐drug antiretroviral combination therapy in primary HIV‐1 infection (2021) (0)
Maintenance of Functional CD57+Cytolytic CD4+T Cells in HIV plus Elite Controllers (2019) (0)
Impact of SARS-CoV-2 pandemic on viral suppression for young adults living with perinatally acquired HIV infection. (2022) (0)
Differences in HIV-Speciﬁc T Cell Responses between HIV-Exposed and -Unexposed HIV-Seronegative Individuals (cid:1) † (2011) (0)
The role of the gut mucosa in protection from HIV-1 in highly exposed persistently seronegative individuals (HEPS) (2009) (0)
O1-S11.03 How many infections are averted by behaviour change after early HIV diagnosis & counselling of MSM? Estimates from a stochastic individual-based model (2011) (0)
Antiretroviral Drug Detection in a Community-Randomized Trial of Universal HIV Testing and Treatment: HPTN 071 (PopART) (2022) (0)
C URRENT OPINION Advancing the HIV cure agenda: the next 5 years (2015) (0)
OPINION Advancing the HIV cure agenda: the next 5 years (2015) (0)
Impact of timing of ART on HIV DNA; findings from HEATHER, an observational cohort study (2016) (0)
Title: Hospital-Based Routine HIV Testing In High-Income Countries: A Systematic Literature Review Running head: Routine HIV Testing In High-Income Countries (2019) (0)
Restriction of V 3 region sequence divergence in the HIV 1 envelope gene during antiretroviral treatment in a cohort of recent (2019) (0)
Bone mineral density optimisation in adults with perinatally acquired HIV infection in routine care (2017) (0)
No evidence of neuroaxonal injury following latency reversal with vorinostat and HIV-1 specific vaccination in the RIVER trial (2019) (0)
Mapping the drivers of within-host pathogen evolution using massive data sets (2019) (0)
HIV/AIDS (2020) (0)
Analysis of prevalence of HIV-1 drug resistance in primary infections (2020) (0)
Implementation of HIV testing is patchy in the UK (2014) (0)
decline in HIV-1 infection (2012) (0)
Sexual and reproductive health needs for young women living with perinatally acquired HIV through the pandemic (2021) (0)
Correction to: Insaka: mobile phone support groups for adolescent pregnant women living with HIV (2021) (0)
Abstracts of the 22nd Annual Conference of the British HIV Association (BHIVA), Manchester, UK, 19-22 April 2016. (2016) (0)
Expression of type I interferon-associated genes at point of antiretroviral therapy interruption predicts time to HIV virological rebound (2020) (0)
Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses. (2021) (0)
Factors associated with uptake of key interventions in the PopART/HPTN 071 trial - a description of trial design and nested research (2013) (0)
P16-42. Characterisation of HIV-1 specific T-cell responses in exposed uninfected individuals from a London cohort (2009) (0)
P6.021 Characteristics of High Risk MSM into a Repeat Self-Sampling HIV-1 Antibody Testing Feasibility and Acceptability Pilot (2013) (0)
PP 8.11 – 00174 Distinct HIV reservoir characteristics among individuals treated during primary versus chronic HIV infection (2022) (0)
Control of HIV viraemia is not enough in perinatal HIV. (2015) (0)
Achieving the UNAIDS 90–90-90 targets: a comparative analysis of four large community randomised trials delivering universal testing and treatment to reduce HIV transmission in sub-Saharan Africa (2022) (0)
Aggregate data for "Towards 90-90: Findings after two years of the HPTN 071 (PopART) cluster-randomized trial of a universal testing-and-treatment intervention in Zambia" (2018) (0)
Abstracts of the Third Joint Conference of the British HIV Association (BHIVA) with the British Association for Sexual Health and HIV (BASHH), 1-4 April 2014, Liverpool, UK. (2014) (0)
Infectious Diseases: Gene Therapy (2006) (0)
Evaluation of an HIV risk score within an outpatient sexual health clinic (2013) (0)
Systematic comparison of HIV-1 Envelope-specific IgG responses induced by different vaccination regimens: Can we steer IgG recognition towards regions of viral vulnerability? (2023) (0)
How do we reach men? Offering HIV testing in evenings and weekends in the HPTN 071 (PopART) community-based trial in South Africa. (2023) (0)
Highlights from the Conference on Retroviruses and Opportunistic Infections 2016 (2016) (0)
P5.23 How much can hiv transmission be reduced in high-risk msm by targeting testing to detect and treat primary hiv infection (PHI)? analysis of a cohort study using an individual-based model (2017) (0)
Lessons from the HPTN 071 (PopART) trial. (2022) (0)
Evaluating virological outcomes in people with HIV on stable antiretroviral therapy with reduced frequency of HIV viral load monitoring during the COVID-19 pandemic. (2023) (0)
The impact of community-based, peer-led sexual and reproductive health services on knowledge of HIV status among adolescents and young people aged 15 to 24 in Lusaka, Zambia: The Yathu Yathu cluster-randomised trial (2023) (0)
Biomarker reveals HIV's hidden reservoir Determining the total amount of HIV DNA in people undergoing antiretroviral therapy could accelerate the development of novel therapies and potential cures for HIV infection. (2014) (0)
Women for science and science for women: Gaps, challenges and opportunities towards optimizing pre-exposure prophylaxis for HIV-1 prevention (2022) (0)
Uptake of medical male circumcision with household-based testing, and the association of traditional male circumcision and HIV infection (2023) (0)
No evidence of neuronal damage as measured by neurofilament light chain in a HIV cure study utilising a kick-and-kill approach (2021) (0)
Temporal trends in cART initiation amongst HIV seroconverters in the UK (2014) (0)
Closing the gap: did delivery approaches complementary to home‐based testing reach men with HIV testing services during and after the HPTN 071 (PopART) trial in Zambia? (2022) (0)
Incoming HIV Virion-Derived Gag Spacer Peptide 2 (p1) is a Target of Effective CD8+ T Cell Antiviral Responses (2020) (0)
Clinical challenge: Deteriorating liver function in TB and HIV co-treatment (2013) (0)
Antigen presenting cell function in HIV-1 infection. (1998) (0)
Diagnosis of primary HIV infection with rapid ART in the HEATHER cohort: towards zero infections (2017) (0)
A screening tool enhances home-based identification of adolescents (2022) (0)
Community-based health workers implementing universal access to HIV testing and treatment: lessons from South Africa and Zambia—HPTN 071 (PopART) the HPTN 071 (PopART) study (2021) (0)
Motivating people living with HIV to initiate antiretroviral treatment outside national guidelines in three clinics in the HPTN 071 (PopART) trial, South Africa (2021) (0)
CD32 expressing doublets in HIV-infected gut-associated lymphoid tissue are associated with a T follicular helper cell phenotype (2019) (0)
A randomised feasibility trial of an intervention to support sharing of HIV status for 18–25-year olds living with perinatally acquired HIV compared with standard care: HIV Empowering Adults’ Decisions to Share—UK/Uganda Project (HEADS-UP) (2020) (0)
Characterisation of Rare Spontaneous HIV Viral Controllers Attending a National UK Clinical Service Using a Combination of Serology and Molecular Diagnostic Assays (2023) (0)
Depressive symptoms and HIV risk behaviours among adolescents enrolled in the HPTN071 (PopART) trial in Zambia and South Africa (2022) (0)
A pilot evaluation of whole blood finger-prick sampling for point-of-care HIV viral load measurement: the UNICORN study (2017) (0)
Lessons from the Research in Viral Eradication of Reservoirs (RIVER) study: Impact of a therapeutic vaccine targeting conserved HIV epitopes on T cell function in treated primary infection (2019) (0)
Attitudes, beliefs and acceptability towards early ART amongst men who have sex with men (MSM) recruited to a UK cohort of HIV seroconverters (2015) (0)
Expression of type I interferon-associated genes at antiretroviral therapy interruption predicts HIV virological rebound (2022) (0)
HLA-Associated Clinical Progression Correlates with Epitope Reversion Rates in Early Human Immunodeﬁciency Virus Infection (cid:1) the SPARTAC Trial Investigators (2008) (0)
Enhanced Normalization of CD 4 / CD 8 Ratio With Earlier Antiretroviral Therapy at Primary HIV Infection (0)
Perinatally infected HIV-positive young adults have low levels of cardioprotective natural antibodies to phosphorylcholine, an epitope of oxidised LDL (2013) (0)
Editorial introduction: The role of ART as prevention of HIV transmission at a population level has become a more recent area of interest. (2010) (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
HIV reservoir size is determined prior to ART initiation and linked to CD8 T cell activation and memory expansion (2019) (0)
Broadly neutralizing antibody responses in the longitudinal primary HIV-1 infection Short Pulse Anti-Retroviral Therapy at Seroconversion cohort (2021) (0)
An exploration of how broadly neutralizing antibodies might induce HIV remission: the 'vaccinal' effect. (2022) (0)
Corrigendum to: community-based health workers implementing universal access to HIV testing and treatment: lessons from South Africa and Zambia—HPTN 071 (PopART) (2021) (0)
Characterization of Rare Spontaneous Human Immunodeficiency Virus Viral Controllers Attending a National United Kingdom Clinical Service Using a Combination of Serology and Molecular Diagnostic Assays (2023) (0)
Intimate Partner Violence (IPV) and Associated Factors in HPTN 071 (PopART) Study Communities in Zambia and South Africa—A Comparison by HIV Status (2022) (0)
4 Post-treatment control or treated controllers? The impact of ART on time to viral rebound in recent seroconverters (2016) (0)
P14.13 Hiv-related stigma and universal testing and treatment for hiv prevention and care: design of an implementation science evaluation nested in the hptn 071 (popart) cluster-randomised trial in zambia and south africa (2015) (0)
Broadly neutralizing antibody responses in the longitudinal primary HIV-1 infection SPARTAC cohort. (2021) (0)
COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2 (2023) (0)
Control of HIV viraemia is not enough in perinatal HIV (2015) (0)

This paper list is powered by the following services:

Other Resources About Sarah Fidler

en.wikipedia.org

What Schools Are Affiliated With Sarah Fidler?

Sarah Fidler is affiliated with the following schools:

Sarah Fidler's Academic­Influence.com Rankings